Maurizio Fava, MD

Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts

  • 145Articles
  • 733.6KReads1
  • 1998–2025Active
  • 434Collaborators
  • 3KCitations2

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

About

Maurizio Fava, MD, is affiliated with the Department of Psychiatry at Massachusetts General Hospital in Boston. With a publication record spanning from 1998 to 2025, Dr. Fava has authored 145 articles focusing on major depressive disorder, treatment-resistant depression, and related psychiatric conditions. His research covers clinical trials and analyses involving antidepressant therapies, including esmethadone, cariprazine, and intranasal esketamine, as well as complementary treatments such as yoga. Dr. Fava's work also addresses topics in suicide, sexual dysfunction, schizophrenia, neurology, and weight management within psychiatric practice.

Publications

JCP
Omega-3 Fatty Acids for MDD With High Inflammation
Original Research

Omega-3 Fatty Acids for MDD With High Inflammation

August 22, 2022

This study investigated whether dosage or inflammation levels affect response to omega-3s in MDD patients.
, , , et al
JCP
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD
Original Research

Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD

May 30, 2022

Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This phase 3 trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion) in the treatment of major depressive...
, , , et al
JCP
Meta-Analysis

Vortioxetine for Major Depressive Disorder

June 15, 2021

Prior meta-analyses have found vortioxetine to be efficacious for depression. Building on those findings, the present meta-analysis examined the effect that placebo response has on drug-placebo effect size in...
, , , et al
JCP
Original Research

Adjunctive Pimavanserin and Sleep/Wakefulness in MDD

December 1, 2020

Adjunctive pimavanserin can reduce depressive symptoms and improve function in patients with major depression and inadequate antidepressant response. This analysis evaluated the effects of adjunctive pimavanserin on sleep/wakefulness disturbances.
, , , et al
JCP
Original Research

Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval

October 13, 2020

This double-blind, randomized, crossover study investigated the effects of a supratherapeutic dose of SPN-812, a drug currently under investigation as a treatment for ADHD, on cardiac repolarization (QTc) in...
, , , et al
JCP
Original Research

Ganaxolone for Persistent Depression

June 9, 2020

Postmenopausal women may be deficient in the neuroactive steroid allopregnanolone. This study examined oral ganaxolone, an allopregnanolone analog, as augmentation therapy in postmenopausal women with inadequate response to traditional...
, , , et al
JCP
Meta-Analysis

Esketamine Augmentation in Major Depressive Disorder

May 26, 2020

The FDA has now approved intranasal esketamine as augmention in treatment-resistant depression, and recent studies of its efficacy have been encouraging. This meta-analysis synthesizes the evidence to provide an...
, , , et al
JCP
Original Research

Adjunctive Pimavanserin in Treatment-Resistant MDD

September 24, 2019

The use of atypical antipsychotics as adjunctive treatment for nonresponsive depression is limited by their side effects. This study explores whether pimavanserin can be both an efficacious and tolerable...
, , , et al
JCP
Original Research

Ziprasidone Augmentation of Escitalopram for Cognition

July 25, 2017

Cognitive deficits are common in depression, but studies suggest that cognitive dysfunction is difficult to treat with antidepressants. Can adding an atypical antipsychotic medication to antidepressant treatment help lessen...
, , , et al
JCP
Original Research

Can an Ancient Art Have a Modern Use?

May 24, 2017

When cultural stigma prevents Chinese Americans from seeking help for their MDD, can an ancient form of mind-body therapy improve their symptoms? Here, researchers investigate the effectiveness of tai...
, , , et al
JCP
Original Research

Secondary Effects of Ziprasidone Augmentation in MDD

April 26, 2017

The atypical antipsychotic ziprasidone is effective in depressed patients who don' t respond to antidepressants, but is it safe? Learn about the clinical relevance of possible cardiac, metabolic, and...
, , , et al
JCP
Original Research

Noradrenergic Symptom Cluster and MDD

March 29, 2017

Adding an SNRI may improve impaired cognition and fatigue, and hence improve the overall depression outcome in patients with partial response to an SSRI. This analysis of trials of...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe